Clinical Trial Authorization (CTA)
You may need to file a request for permission from the Medicines & Healthcare products Regulatory Agency (MHRA) or European Medicine Agency (EMA) if you want to start human clinical trials of a new medicine.
More information about Clinical Trial Authorization (CTA)
Trials,product,studies,document,forms,time,investigator,clinical trials,qualities,clinical trial applications,medicinal product,safety,process,regulatory requirements,treatment,application forms,format,calendar days,active ingredient,clinical trial sponsors.
Clinical trial protocols,clinical trial approvals,investigational product,health,safety reporting requirements,guidance document,Ethics Committee,time of submission,material,legal requirements,clinical trial subjects,clinical trial sites.
Clinical trial authorization,application process,submission process,study protocol,dosage form,letters,acknowledgement letter,substances,active substance,electronic format,causal relationship,marketing applications,investigational drugs,human subjects,Health Canada,safety evaluations,informed consent process.
Comparative bioavailability studies,clinical studies,Ethics Committee >,informed consent form,time of application,medical treatment,acceptance,qualified investigator,biological materials,gene therapies,ongoing trial,complete document,future time,treatment period,principal investigator,Quality (Chemistry and Manufacturing,cover letter,Harmonisation,HC/SC 3011,requests for clarification,TGA Business Services,online portal,ethical approvals,Clinical Trial Application-Amendments,clinical trial drug supplies,trial amendment,commercial product,clinical product,drug product manufacturer,release drug product,National Health Surveillance Agency,HCNotice-CA-ICH-GCPs Health Canada,Health Canada’s,Health Products and Food Branch,Clinical Safety Data Management: Definitions and,Safety Data Management: Definitions and Standards for Expedited Reporting,fermentation process,official document,Human Research Ethics Committee,National Research Ethics Commission,extension in treatment duration,acceptance criterion,acceptance criterionNotification5,acceptance criteria,Quality Information Summary,drug substance intermediate,clinical material,International Council for Harmonisation,-implemented International Council for Harmonisation,eCTD format.